Research Progress on PANoptosis in Ischemia-reperfusion Injury Diseases
10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2025.0404
- VernacularTitle:泛凋亡在缺血-再灌注损伤疾病中的研究进展
- Author:
Xiang GAO
1
;
Bo FENG
1
Author Information
1. 河南中医药大学第一附属医院急诊科,河南 郑州 450000
- Publication Type:Journal Article
- Keywords:
PANoptosis;
PANoptosome;
ischemia-reperfusion injury;
programmed cell death;
review
- From:
Journal of Sun Yat-sen University(Medical Sciences)
2025;46(4):574-582
- CountryChina
- Language:Chinese
-
Abstract:
PANoptosis,a newly characterized form of programmed cell death,exhibits hybrid molecular features of pyroptosis,apoptosis,and necroptosis,orchestrated by upstream PANoptosomes.This process is critically implicated in the pathophysiological progression of infectious and inflammatory disorders.Previously,these pathways of programmed cell death were considered mutually exclusive signaling systems.Previously advanced molecular interrogation has revealed intricate cross-regulatory networks among them.Researchers have formally defined this inter-pathway communication mechanism as PANoptosis.Emerging evidence implicates PANoptosis in diverse human pathologies,including infectious diseases,neurological disorders,and malignancies.Notably,PANoptosis has emerged as a critical modulator of ischemia-reperfusion injury(IRI)-associated pathologies,though its precise regulatory mechanisms remain incompletely delineated.A comprehensive understanding of the research advances in PANoptosis within IRI-related pathologies,coupled with the systematic elucidation of its regulatory mechanisms,holds transformative potential for therapeutic breakthroughs in disease management.As a feasible intervention target,PANoptosis has proven promising in studies and become a focus of intense research.This comprehensive review critically analyzes current knowledge on PANoptosis,including its definitions,molecular hallmarks,regulatory mechanisms,and pathophysiological correlations in IRI,to catalyze the development of transformative therapeutic strategies and pertinent medications for IRI management.
